News & Updates

The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.

Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.

People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.

In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRAS^G12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRAS^G12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.

In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.